XML 22 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
 9 Months Ended
Mar. 31, 2014
Mar. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (20,736) $ (14,165)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 1,416 592
Loss on sale of property and equipment 35   
Stock-based compensation to employees, directors and non-employee consultants 4,019 2,105
Stock compensation to investor relations consultants 159 278
Decrease (increase) in other accounts receivable 57 (515)
Increase in prepaid expenses (55) (448)
Increase in trade payables 585 209
Increase in other accounts payable and accrued expenses 726 1,612
Decrease in deferred revenues (285) (584)
Decrease in advance payment from United Therapeutics (132) (1,009)
Linkage differences and Increase (decrease) interest on short and long-term deposit and restricted lease deposit (27) (158)
Accretion of discount, amortization of premium and changes in accrued interest from marketable securities 267 169
Loss from sale of available-for-sale marketable securities 108 21
Accrued severance pay, net 98 19
Net cash used in operating activities (13,765) (11,874)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of property and equipment (1,436) (3,247)
Repayment of (Investment in) short-term deposits 1,945 (1,408)
Repayment of (Investment in) long-term deposits (3) 489
Repayment of long-term restricted deposit 117 12
Proceeds from sale of available-for-sale marketable securities 3,875 679
Proceeds from redemption of available-for-sale marketable securities 687 351
Investment in available-for-sale marketable securities (8,809) (2,537)
Net cash used in investing activities (3,624) (5,661)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Issuance of common stock and warrants, net of issuance costs 10,149 34,106
Exercise of options and warrants 1,871 1,861
Net cash provided by financing activities 12,020 35,967
Increase (decrease) in cash and cash equivalents (5,369) 18,432
Cash and cash equivalents at the beginning of the period 9,007 9,389
Cash and cash equivalents at the end of the period 3,638 27,821
Supplemental disclosure of cash flow activities:    
Taxes paid due to non-deductible expenses 43 15
Supplemental disclosure of non-cash activities:    
Purchase of property and equipment on credit 146 1,738
Issuance of common stock under CHA Agreement (Note 1c) 10,414   
Stock based compensation to contractor    $ 1,400